CoreAge Rx vs ARSYNL Rx
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and ARSYNL Rx head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 63 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make ARSYNL Rx a bad call — it's best for readers comparing a clearly identified injection with other advertised routes who will verify the formulation and refill agreement. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | ARSYNL Rx |
|---|---|---|
| Brief Score | 94/100 (A) | 63/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | Injection page advertises $219/month One-month compounded semaglutide + B12 plan; medication, provider review, supplies and delivery described included. Selected dose and supplied quantity unconfirmed; earlier $233/month listing is historical. Exact refill cancellation deadline needs confirmation. Full price detailsCompounded semaglutide injection offered; complete selected-prescription quote unknown; current product page advertises $219/month one-month plan with medication and care, while earlier listing from $233/mo is historical |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | Injection page advertises $269/month One-month plan; product title says B12 while treatment body says B6. Confirm exact formulation and supplied quantity. Earlier $366/month listing is historical. Transdermal spray is separate: $269/month or $759 once for three months, with a four-week bottle described. Full price detailsCompounded tirzepatide injection offered; exact added ingredient and complete selected-prescription quote unknown; current injection page advertises $269/month one-month plan but title says B12 and body says B6; earlier listing from $366/mo is historical |
| Coverage | US only; restrictions by state, confirmed at intake | U.S. service advertised; eligibility restrictions vary by therapy, medication and patient state |
| Brand-name access | Not confirmed | References to Wegovy, Ozempic, Mounjaro or Zepbound ingredients and trial results do not establish an advertised branded prescribing program. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
ARSYNL Rx: Current injection pages advertise $219/month semaglutide and $269/month tirzepatide; selected formulation/supply remain unconfirmed and tirzepatide B12/B6 wording conflicts. Spray is a separate route.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.